Targeting IL-33 and TSLP: A Novel Approach to Modulate Type 2 and Non-Type 2 Inflammatory Pathways in Pemphigus Vulgaris.

Rituxan (rituximab) - Roche

http://www.ncbi.nlm.nih.gov/pubmed/42726400

Benjamin Ungar; Brandon R Block; Gabriela Soto-Canetti; Jaanvi Mehta; Jonas Adalsteinsson; Jordan Talia; Kristina Navrazhina; Tammy Ehimwenma-Point Du Jour

Sep 12, 2026